MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jul 27, 2021
Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor Jul 26, 2021
Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol ‘AWKNF’ Jul 26, 2021
Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq Under the Symbol “FTRP” Jul 23, 2021
